emavusertib
Generic: CA-4948·Code: CA-4948
emavusertib: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| CURIS INC (CRIS) | Phase 2 |
Clinical Trials (1)
A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
FDA Decisions
FDA_MeetingCHMP scientific advice: single-arm TakeAim study could support a CMA; ORR as primary endpoint supported; ~45 patients may suffice; safety database size and contribution of each agent required.(CRIS)
Frequently asked questions
Who is developing emavusertib?
emavusertib is being developed by CURIS INC.
How many clinical trials involve emavusertib?
BioSniper tracks 1 clinical trial involving emavusertib.
What is emavusertib's latest FDA decision?
The most recent tracked FDA decision for emavusertib is FDA_Meeting for CHMP scientific advice: single-arm TakeAim study could support a CMA; ORR as primary endpoint supported; ~45 patients may suffice; safety database size and contribution of each agent required..
Get deeper analysis on emavusertib
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis